Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Clinical and MRI outcomes (n = 70).
| Outcome | |
|---|---|
| Relapses in RMS patients | |
| ARR 12 months prior to study inclusion | 1.3 |
| ARR after ocrelizumab initiation | 0.02 |
| Disability progression (EDSS) | 1/70 (1.4%) |
| MRI | |
| Patients with Gadolinium-enhancing lesions at: | |
| Baseline | 40/70 (57%) |
| 4–6 months | 1/70 (1.4%) |
| 12 months | 0/46 (0%) |
| New or enlarging T2-hyperintense lesions at 12 months | 1/46 (2.2%) |
ARR, annualized relapse rate; RMS, relapsing multiple sclerosis.
